Essentials Anticoagulation in patients with factor X deficiency is an evidence-poor area. A patient with factor X deficiency was anticoagulated with warfarin followed by rivaroxaban. Warfarin may be a safer anticoagulant option than rivaroxaban in hereditary factor X deficiency. A baseline coagulation screen should be performed prior to commencement of anticoagulation. Summary: We report a case of a previously undiagnosed factor X deficiency in an 83-year-old man who had no previous bleeding history despite multiple hemostatic challenges. He was anticoagulated with warfarin for atrial fibrillation without bleeding complications; however, major hemorrhage occurred soon after a switch to rivaroxaban.
CITATION STYLE
Sayar, Z., Speed, V., Patel, J. P., Patel, R. K., & Arya, R. (2018). The perils of inhibiting deficient factors. Journal of Thrombosis and Haemostasis, 16(8), 1535–1536. https://doi.org/10.1111/jth.14195
Mendeley helps you to discover research relevant for your work.